RNA editing-dependent epitranscriptome diversity in cancer stem cells

Jiang, Qingfei; Crews, Leslie; Holm, Frida; Jamieson, Catriona

doi:10.1038/nrc.2017.23

Cited by 103 publications

(117 citation statements)

References 148 publications

(216 reference statements)

Supporting

Mentioning

113

Contrasting

Order By: Relevance

“…Sixth, whether CSCs should be activated or arrested is an open question in cancer therapy. 652 Seventh, novel signaling and more regulatory levels, such as RNA editing, 653 epigenetics, 654 and cellular metabolism, 655 should be considered in cancer therapy because they also contribute to the stemness of CSCs. Eighth, some inhibitors that target CSC signaling are not very specific, and so new inhibitors need to be designed.…”

Section: Discussionmentioning

confidence: 99%

Targeting cancer stem cell pathways for cancer therapy

Yang

Shi

Zhao

et al. 2020

Sig Transduct Target Ther

1,318

998

View full text Add to dashboard Cite

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy. These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC. In addition, many intracellular signaling pathways, such as Wnt, NF-κB (nuclear factor-κB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs. Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials. This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.Signal Transduction and Targeted Therapy (2020) 5:8; https://doi.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting cancer stem cell pathways for cancer therapy

Yang

Shi

Zhao

et al. 2020

Sig Transduct Target Ther

1,318

998

View full text Add to dashboard Cite

show abstract

“…RNA editing by ADAR is the most prevalent type of RNA editing and occurs mostly in non-coding regions where inverted repeated sequences are likely to form dsRNA structures, which functions as substrate. It has recently attracted attention as cancer driver for its role in cancer stem cell maintenance, possibly linked also to reduced production of mature miRNA due the impairment of their processing by Drosha after editing of hairpin structures in primitive miRNA (Nishikura, 2016, Jiang et al, 2017. Although we could not evaluate miRNA abundance or mutations due to the method used to extract RNA, it is worth noting that YAP activation has been shown to decrease the activity of Drosha (Mori et al, 2014), therefore RNA editing and YAP/TAZ activation may converge on profound modification of mature miRNA.…”

Section: Discussionmentioning

confidence: 99%

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutations

Rehrauer

Blum

et al. 2017

Preprint

View full text Add to dashboard Cite

SummaryChronic exposure to intraperitoneal asbestos triggered a marked response in the mesothelium well before tumor development. Macrophages, mesothelial precursor cells, cytokines and growth factors accumulated in the peritoneal lavage. Transcriptome profiling revealed YAP/TAZ activation in inflamed mesothelium with further activation in tumors, paralleled by increased levels of cells with nuclear YAP/TAZ. Arg1 was one of the highest upregulated genes in inflamed tissue and tumor. Inflamed tissue showed increased levels of single nucleotide variations, with an RNA-editing signature, which were even higher in the tumor samples. Subcutaneous injection of asbestos-treated, but tumor-free mice with syngeneic mesothelioma tumor cells resulted in a significantly higher incidence of tumor growth when compared to naïve mice supporting the role of the environment in tumor progression.

show abstract

“…Recent researches have demonstrated positive roles of aberrant splicing in carcinogenesis (63–71). The full-length Ets1 (p51-Ets1) and Ets1 ΔVII (p42-Ets1) isoforms (57) have key distinctions regarding protein-protein interactions, DNA-binding kinetics, and transcriptional target specificity (72).…”

Section: Ets1 and Ets2mentioning

confidence: 99%

Aberrant expression of ETS1 and ETS2 proteins in cancer

Fry

Inoue

2018

Cancer Rep Rev

View full text Add to dashboard Cite

The ETS transcription factors regulate expression of genes involved in normal cell development, proliferation, differentiation, angiogenesis, and apoptosis, consisting of 28 family members in humans. Dysregulation of these transcription factors facilitates cell proliferation in cancers, and several members participate in invasion and metastasis by activating gene transcription. ETS1 and ETS2 are the founding members of the ETS family and regulate transcription by binding to ETS sequences. They are both involved in oncogenesis and tumor suppression depending on the biological situations used. The essential roles of ETS proteins in human telomere maintenance have been suggested, which have been linked to creation of new Ets binding sites. Recently, preferential binding of ETS2 to gain-of-function mutant p53 and ETS1 to wild type p53 (WTp53) has been suggested, raising the tumor promoting role for the former and tumor suppressive role for the latter. The oncogenic and tumor suppressive functions of ETS1 and 2 proteins have been discussed.

show abstract

RNA editing-dependent epitranscriptome diversity in cancer stem cells

Cited by 103 publications

References 148 publications

Targeting cancer stem cell pathways for cancer therapy

Targeting cancer stem cell pathways for cancer therapy

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutations

Aberrant expression of ETS1 and ETS2 proteins in cancer

Contact Info

Product

Resources

About